Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Cenix BioScience GmbH. (5/5/14). "Press Release: Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG". Dresden.

Organisations Organisation Cenix BioScience GmbH
  Group Cenix BioScience (Group)
  Organisation 2 Bayer Pharma AG
  Group Bayer (Group)
Products Product drug target identification
  Product 2 RNAi technology
Index term Index term Bayer–Cenix BioScience: drug target discovery, 201405– supply research service €na RNAi-based techn to identify targets for undisclosed indication
Person Person Sachse, Christoph (Univ Tübingen 201504– Site Head Berlin NMI TT Pharmaservices before siTools + Cenix BioScience)

Cenix BioScience GmbH (Cenix), a leading preclinical contract research provider and technology developer specialized in RNAi-based genomics and high content screening-driven pharmacology, today announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).

Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.

Financial terms were not disclosed.

About Cenix BioScience

With operations in Germany and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 15th year, Cenix has established unrivaled scientific and commercial track records in this field, successfully advancing therapeutic programs for numerous industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients, is driven by the consistent application of industrial best practices through highly customized, multi-staged projects carefully designed for maximal strategic value and accountability, with minimized risk and full data transparency. More information:

Dr. Christoph Sachse
Director Cell-based Services

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH.

Record changed: 2017-04-02


Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Cenix BioScience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top